A cura di Alessandra Russo. Specialista in Tossicologia Medica. Messina
|
Principio attivo |
Effetto |
|
Candesartan (1) |
Possibile aumento del rischio di severa neutropenia. |
|
Fenitoina (2-4) |
Possibile riduzione dell’efficacia della fenitoina. |
|
Vaccini con virus vivi (5) |
Possibile aumento del rischio di infezione. |
|
Warfarin (6) |
Possibile aumento del rischio di valori elevati di INR e conseguente sanguinamento. |
Bibliografia
- Katsube Y, et al. Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia. Int J Clin Pharmacol Ther 2018; 56: 328-336.
- Dofferhoff ASM, Berendsen HH. Decreased phenytoin level after carboplatin treatment. Am J Med 1990; 89: 247-248.
- Grossman SA, et al. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 1989; 87: 505-510.
- Riva R, et al. On the interaction between phenytoin and antineoplastic agents (letter). Ther Drug Monit 1985; 7: 123-126.
- Centers for Disease Control and Prevention: General Recommendations on Immunization. MMWR Jan 28, 2011; 60 (2): 1-64.
- Le AT, et al. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 1997; 31: 1006-1008.
Link
– Potenziale rischio di sindrome da encefalopatia posteriore reversibile associata a carboplatino